Colchicine's effects on platelet function in coronary artery disease patients
The Effect of Colchicine on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad and Tobago. The Pilot ECLIPSE Study.
This study is testing if taking colchicine can improve blood platelet function and help prevent heart problems in patients with stable coronary artery disease who are already on other heart medications.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of The West Indies Academic / other |
| Locations | 1 site (Saint Augustine) |
| Trial ID | NCT06567678 on ClinicalTrials.gov |
What this trial studies
This study investigates how colchicine, an FDA-approved drug for secondary prevention in coronary artery disease, affects platelet reactivity in patients already on dual antiplatelet therapy. By focusing on patients with stable coronary artery disease, the research aims to understand the anti-inflammatory properties of colchicine and its potential benefits in reducing cardiovascular events. Participants will receive colchicine 0.5 MG orally twice daily to assess its impact on their cardiovascular health.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with stable coronary artery disease who are currently on dual antiplatelet therapy.
Not a fit: Patients who are already taking colchicine will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management of coronary artery disease by improving platelet function and reducing cardiovascular events.
How similar studies have performed: Previous studies have shown promising results regarding the use of colchicine in coronary artery disease, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with stable coronary artery disease. * Patients older than 18 years of age. * Patients currently on dual anti platelets, aspirin and clopidogrel Exclusion Criteria: • Patients already on colchicine
Where this trial is running
Saint Augustine
- The University of The West Indies — Saint Augustine, Trinidad and Tobago (Recruiting)
Study contacts
- Principal investigator: Naveen Seecheran — The University of The west Indies, Saint Augustine, Trinidad and Tobago.
- Study coordinator: Naveen Seecheran
- Email: nseecheran@gmail.com
- Phone: 18687537686
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.